Pharmabiz
 

Fibromyalgia drug result positive: Pfizer

BostonSaturday, May 5, 2007, 08:00 Hrs  [IST]

Significantly more patients treated with Pfizer's Lyrica reduced their pain by 50 per cent or more compared with placebo, according to study results presented at the American Academy of Neurology annual meeting. Clinically, this outcome would equate to a patient with severe pain reporting a reduction to mild to moderate pain. Fibromyalgia is one of the most common chronic, widespread pain conditions and is thought to result from neurological changes in how patients perceive pain. Fibromyalgia is usually accompanied by poor sleep, stiffness and fatigue. The pain of fibromyalgia can hamper a patient's ability to work and often results in increased medical costs and disability. There are no medications approved to treat fibromyalgia. "A growing body of evidence is defining the biology behind fibromyalgia that causes such devastating and constant pain," said Dr I Jon Russell, one of the study's authors and associate professor of medicine in the division of clinical immunology and rheumatology and director of the university clinical research centre at the University of Texas Health Science Centre, San Antonio. "A reduction in pain is critical for people living with this condition. With positive new data and new treatments on the horizon, the outlook for people with fibromyalgia has never been better." The 14-week placebo-controlled study included 745 patients with fibromyalgia who were randomised to receive Lyrica (300mg, 450mg or 600mg) or placebo daily. Patients were asked to measure their pain on a scale of zero to 10; the baseline score for study participants was 6.7 on this 10-point scale. The study found that patients receiving 600mg a day of Lyrica reduced their pain by 2.05 on the pain scale; 2.03 for patients taking 450mg a day; 1.75 for patients taking 300mg a day, and 1.04 for patients taking placebo. Significantly more patients treated with Lyrica reduced their pain by 50 percent or more compared with placebo. Of those patients taking 600mg of Lyrica a day, 30 percent said their pain was cut in half or better; 27 per cent of those taking 450mg a day and 24 per cent of those taking 300mg also reported this level of pain relief. Of those taking placebo, 15 per cent reported pain reduction of 50 percent or greater. Patients receiving Lyrica also reported significant improvements in overall health status and outcomes, including measures such as physical function and ability to perform everyday tasks. The most common side effects in the study were dizziness and somnolence, followed by weight gain, headache and peripheral edema. The results of these data were submitted to the FDA as part of a supplemental New Drug Application for Lyrica for the treatment of fibromyalgia. Pfizer also intends to pursue a fibromyalgia indication in other major markets worldwide. In the United States, Lyrica (pregabalin) capsules CV is approved for the management of neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia, and in epilepsy for the adjunctive treatment of partial onset seizures in adults. Outside of the United States, Lyrica is approved for use in adults for the treatment of various peripheral and central neuropathic pain indications, including diabetic pain and post-herpetic neuralgia, pain resulting from spinal cord injury, and adjunctive therapy for partial seizures in more than 60 countries.

 
[Close]